AbbVie Inc. (APGE) Earnings Call Transcripts

AbbVie Inc.'s Latest Earnings Call - June 22, 2026

In the Q2 2026 earnings call, AbbVie Inc. announced the acquisition of Apogee Therapeutics, which is expected to significantly enhance their immunology portfolio. The acquisition, valued at $10.9 billion, aims to bolster AbbVie's pipeline with assets like zumilokibart, anticipated to drive mega blockbuster sales. The transaction is projected to be accretive to earnings by 2032. No changes were made to existing revenue or earnings guidance.

Reported metrics

Guidance from management

Management maintained their commitment to a strong and growing dividend and financial flexibility for additional business development. No changes to existing guidance were announced.

What management said

Thanks, Scott. We will now open the call for questions in the interest of hearing from as many analysts as possible over the remainder of the call. [Operator Instructions]. Operator, first question, please.

Sure. Chris, this is Scott. I'll start with the first question and then maybe turn it over to Jeff on your second question regarding access. So as I said in my remarks, the majority of the value is associated with zumilokibart. And with respect to indication wise, the bulk of that relates to AD as well. So we've not ascribed a certain percentage to it. Obviously, we're going to go through our analysis, and you'll see...

What analysts pressed on

Analysts questioned the competitive landscape in atopic dermatitis, particularly against Dupixent and potential biosimilars. Concerns were raised about the need for head-to-head trials and formulary access challenges.

Main topics on the call

• Acquisition of Apogee Therapeutics — AbbVie announced the acquisition of Apogee Therapeutics for $10.9 billion, adding differentiated assets to its immunology portfolio. The acquisition is expected to create significant shareholder value with 'mega blockbus...
• Immunology Portfolio Expansion — The acquisition adds zumilokibart, a promising asset for atopic dermatitis, which demonstrated strong efficacy in Phase II trials. Management highlighted its potential as a 'best-in-category profile' with convenient dosi...
• Financial Impact of Acquisition — The acquisition is expected to be $0.14 dilutive to 2026 EPS and $0.46 dilutive to 2027 EPS, with accretion anticipated by 2032. The deal will be funded with debt, but AbbVie aims to maintain a net leverage ratio of 2x w...
• Pipeline and Future Growth — AbbVie plans to leverage Apogee's assets to drive growth in immunology, neuroscience, and oncology. The company sees significant opportunities in areas like asthma and COPD, with ongoing development plans.

Read the full AbbVie Inc. transcript (June 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 15 AbbVie Inc. earnings call transcripts on record, spanning March 5, 2024 to June 22, 2026. Based on this history, AbbVie Inc. reports quarterly. The most recent call on file is dated June 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

APGE

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

15

First call

March 5, 2024

Most recent

June 22, 2026

Reporting cadence

quarterly